Pharmaceutical R&D functions at its best in small, agile and innovative SMEs. Replacing state subsidies and grant funding for research with start-up and development capital, would bring productivity improvements, says Mark Bloomfield, CEO of French biotech Polyplus Transfection
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.